Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Aura Biosciences, Inc.NASDAQ: AURA

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities falls 6.6% from a year ago

Other current liabilities stood at $2.97M at the end of Q1 FY2026, down 6.6% from a year earlier and down 52.5% from the prior quarter. Over 3 fiscal years it compounded at +27.3% a year.

Context

  • Other current liabilities amounted to 2.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
  • Other current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps falling in the next quarterly balance sheet after a -6.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.97M-52.5% QoQ
Last fiscal yearDec 2025
$6.25M+910.8% YoY
Year agoMar 2025
$3.18M-6.6% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.6%——
1 year+910.8%——
3-year CAGR+27.3%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
6.25M USD
Year-over-year change
+910.8%
4-year CAGR
+23.9%

Other Current Liabilities vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -6.6% is the 8th highest of 9, against a peer median of +53.7%.
  • Other current liabilities amounts to 2.2% of total assets for AURA, versus a peer median of 6.5%.
AURA Competitors
Other Current Liabilities for AURA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMNMImmunome, Inc.Sep 2026$40.97M USD+359.6%+97.7%8.1%
OCSOculis Holding AGMar 2026CHF 35.44M CHF+137.3%+32449.2%14.6%
MGNXMacroGenics, Inc.Mar 2026$18.45M USD—-8.5%8.5%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$15.27M USD+1428.1%+326.4%10.6%
BCYCBicycle Therapeutics plcMar 2026$9.58M USD-56.5%+8.5%1.5%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$8.89M USD+58.9%+20.6%3.1%
AKTSAktis Oncology, Inc.Mar 2026$5.05M USD—+56.4%0.9%
OCGNOcugen, Inc.Mar 2026$4.16M USD+12.8%+29.1%7.3%
AURAAura Biosciences, Inc.Mar 2026$2.97M USD-6.6%+27.3%2.2%
OTLKOutlook Therapeutics, Inc.Mar 2026$1.24M USD-4.8%+27.8%5.7%
WHWKWhitehawk Therapeutics IncMar 2026$778K USD+48.5%+26.2%0.6%
Peer median (excluding AURA) —+53.7%+28.4%6.5%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents149.06M121.58M41.06M31.69M59.52M
Short-term Investments067.23M185.09M119.4M84.73M
Net Receivables00000
Inventory00000
Other Current Assets89K5.72M3.83M1.83M1.18M
Total Current Assets153.7M196.7M231.79M160.62M149.74M
Property, Plant & Equipment (Net)6.2M26.04M22M20.59M18.45M
Goodwill00000
Intangible Assets00000
Long-term Investments0768K000
Tax Assets00000
Other Non-current Assets125K423K1.28M1.29M1.24M
Total Non-current Assets6.33M27.23M23.28M21.88M19.69M
Total Assets160.03M223.94M255.08M182.5M169.43M
Account Payables2.4M2.92M1.79M2.3M1.55M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.65M3.03M935K618K6.25M
Total Current Liabilities7.36M10.46M12.36M14.91M18.38M
Long-term Debt000014.13M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities360K17.9M16.87M15.62M14.13M
Total Liabilities7.72M28.35M29.23M30.53M32.52M
Common Stock00000
Retained Earnings(152.14M)(210.9M)(287.31M)(374.23M)(480.42M)
Accumulated OCI0(72K)539K263K(102K)
Other Stockholders Equity001K00
Minority Interest00000
Total Equity152.32M195.58M225.85M151.97M136.91M
Total Debt975K20.86M19.56M18.77M17.38M
Net Debt(148.09M)(100.72M)(21.51M)(12.92M)(42.14M)

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.